Valsartan Increases Circulating Adiponectin Levels without Changing HOMA-IR in Patients with Type 2 Diabetes Mellitus and Hypertension  

Oleh:

J-M, Lee ; J-H, Kim ; H-S, Son ; E-G, Hong ; J-M, Yu

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The Journal of International Medical Research vol. 38 no. 01 (Jan. 2010), page 234-241.
Topik: type 2 diabetes mellitus; hypertension; valsartan; angiotensin II receptor blocker; adiponectin; insulin sensitivity

Ketersediaan

Perpustakaan FK Nomor Panggil: J11.K.2010.01 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Evaluating increasing circulating adiponectin levels is becoming an important strategy in the prevention of diabetes mellitus and cardiovascular events. This study was designed to investigate the effect of the angiotensin II receptor blocker valsartan on blood adiponectin levels and insulin sensitivity in patients with type 2 diabetes and mild-to-moderate hypertension. A total of 91 Korean patients were treated with 80 mg/day valsartan for 4 weeks followed by 160 mg/day for a further 8 weeks. Blood pressure, adiponectin levels and metabolic parameters were measured before and after treatment. The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as an insulin sensitivity index. Valsartan significantly decreased mean blood pressure and increased circulating adiponectin levels. There were no differences in metabolic parameters, including HOMA-IR, glycosylated haemoglobin and lipid levels before and after treatment. These results indicated that valsartan increases circulating adiponectin levels, but does not change insulin sensitivity in patients with type 2 diabetes and mild-to-moderate hypertension.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali